BOTHELL, Wash., June 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast its upcoming breakfast symposium with key opinion leaders. The event will focus on the company’s lead commercial product candidate eptinezumab, and the evolving migraine treatment landscape, and will be held on Wednesday, June 26, 2019 from 8:30 a.m. to 10:30 a.m. ET in New York, NY.
Guest speakers presenting at the event include:
- Christopher Gottschalk, M.D., F.A.H.S., Chief, Division of General Neurology, Yale School of Medicine, Assistant Professor of Neurology, Yale School of Medicine
- Lawrence Newman, M.D., Professor, Department of Neurology, New York University Langone Medical Center, Director, Headache Division, New York University Langone Medical Center
A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at www.alderbio.com. A replay of the webcast will be available on the Alder BioPharmaceuticals’ website for 90 days following the event.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is an investigational monoclonal antibody (mAb) delivered by infusion that inhibits the calcitonin gene-related peptide (CGRP) for the prevention of migraine. If approved by the U.S. Food and Drug Administration, it will be the first quarterly, anti-CGRP infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contact:
Stern Investor Relations, Inc.